PT -期刊文章AU -尼尔Graff-Radford盟David Knopman AU -艾伦笔者盟-劳拉·科克盟-托马斯·摩斯TI -正常压力脑积水和脉压(一):ARIC研究(P05.033) DP - 2012年4月25日TA -神经病学PG - P05.033 P05.033 VI - 78 IP - 1补充4099 - //www.ez-admanager.com/content/78/1_Supplement/P05.033.short首页 4100 - //www.ez-admanager.com/content/78/1_Supplement/P05.033.full所以Neurology2012 4月25日;78 AB -目的:评估协会之间的脉压(systolic-diastolic)和心室大小(VS)和沟的扩大(SW)最初在一个中年人,混血儿群体在社区(ARIC)研究动脉粥样硬化的风险。背景增加脉压与一个气球在羊心室在数小时内造成脑积水(Exp 1978 59:30神经)。Kaolin-induced脑积水狗没有脉络丛时导致脑积水手术切除。一组患者脑脊液吸收异常但白质变化受益于分流手术(J Neurosurg。2011; 114:1432。)这些观察提高的可能性,脉压可以在一组发展中发挥作用。设计/方法:最初的磁共振(MR)扫描和血管危险因素评估进行1812年ARIC参与者在1994 - 95年。在2004 - 6中,1130名参与者进行了重复扫描先生先生被评为使用验证9分制VS和西南。多元逻辑回归分析被用来评估之间的联系英国石油(BP)措施,包括脉冲扫描先生之间的压力和改变一个或多个成绩在VS和SW控制了年龄、性别和种族。在基线结果:1112名参与者(304年385黑人女性,200黑人,白人女性和223白人男性)有一个平均年龄为61.7±4.3年。在基线调整模型中的脉压与恶化VS(比值比(或)1.19,95% CI 1.01 - -1.40)是收缩压(或1.28,95%可信区间1.03 - -1.58)。相比之下,舒张压与减少VS(或0.76可信区间0.62 - -0.94)。Conclusions: While systolic BP and pulse pressure are associated with future development of increased VS, diastolic BP has the opposite effect. The findings are consistent with the animal literature that high systolic pressure with low diastolic pressure (that is, increased pulse pressure) predisposes to risk of future increased VS. This finding has important implications for treatment of systolic hypertension and possible NPH development.Supported by: The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This work was also supported by grant R01- HL70825. The authors thank the staff and participants of the ARIC study for their important contributions. (This is related to ARIC MS #1553).Disclosure: Dr. Graff-Radford has received personal compensation for activities with Codman as a participant on a scientific advisory board. Dr. Graff-Radford has received personal compensation in an editorial capacity for the Neurologist. Dr. Graff-Radford has received research support from Janssen Pharmaceuticals, Inc., Pfizer Inc, Medivation, Inc., Forrest Laboratories and Allon Therapeutics Inc. Dr. Knopman has received personal compensation for activities with Lilly Pharmaceuticals as a data safety monitoring board member. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Elan, Forest, and Baxter. Dr. Penman has nothing to disclose. Dr. Coker has nothing to disclose. Dr. Mosely has nothing to disclose.Wednesday, April 25 2012, 14:00 pm-19:00 pm